Mazdutide: First-in-Class Dual Agonist Approved in China (2026)

Most research peptides live on a pile of animal studies and a wall of forum posts. Mazdutide is one of the rare ones where the conversation is standing on published human trials — and on a real regulatory decision. It became the first glucagon/GLP-1 dual agonist to win approval from China's regulator for chronic weight management, which is genuinely newsy. So the honest question is not whether anything happened in the studies, but exactly what the trials reported, in whom, and where the research-grade vial you can actually buy stops matching that story.

What it is, in plain English

Mazdutide (also called IBI362 or LY3305677) is a peptide that acts as a dual agonist. In plain terms: the familiar weight-management drugs pull one or two metabolic levers, and mazdutide is researched as pulling the GLP-1 lever plus the glucagon lever. That glucagon action is the headline difference and the reason researchers got interested — glucagon-receptor signalling is studied for effects on energy expenditure and liver fat, which the GLP-1-only peptides do not target. It is a different combination of levers, not a copy of the ones most people already know.

What it's commonly researched for

The headline use is weight management, and this is where mazdutide has the most going for it. It was studied in humans for body-weight and metabolic endpoints, and people report interest in it for exactly that reason. Because of the glucagon arm, it is also researched for liver-fat outcomes. The caveat that travels with every one of those lines: it is not FDA-approved in the United States, it is still investigational there, and effects in humans are still being studied. Front-loading the reason people care is fair; pretending the picture is finished is not.

What researchers actually studied

In a published phase-2 randomized controlled trial of Chinese adults with overweight or obesity, mazdutide was associated with reductions in body weight versus placebo over the study period, and the trial also reported changes in metabolic and liver-related measures. A later phase-3 program, GLORY-1, reported placebo-adjusted weight reductions and supported the regulatory submission in China. That is genuine tier-A human evidence, which almost no research peptide can claim. Most of it comes from one population studied in one country, so how well the reported figures generalize is a fair open question the data itself raises.

What people report

In online communities, some people describe noticeable appetite changes and weight loss, sometimes faster than they expected. Others describe nausea or diarrhea strong enough to be the dealbreaker, the reduced-appetite pattern that shows up across this drug class, or questions about what the glucagon arm might mean for heart rate or the liver over time. A recurring theme worth flagging is that stopping tends to reverse the changes. These are anecdotes, not evidence, and there is no way to know how representative any single story is — the point of listing the good and the bad together is that both are real parts of what people say.

What the evidence does not show

The human data is real but geographically narrow and, for the glucagon arm, still maturing. A trial that reads out in one population does not settle how a compound behaves across everyone who would eventually use it, and phase-3 success in one country is not the same as the long-term safety record that comes only from years of wide use. The data also says nothing reassuring about the research-grade material sold for lab use, which is not the pharmaceutical-grade product the trials ran. Reading the strong headlines as a finished, universal verdict is exactly the leap the evidence does not support.

Known and theoretical risks

The most commonly reported effects in trials and user accounts are gastrointestinal — nausea, diarrhea, and decreased appetite — the pattern seen across this class of metabolic compounds. Because the glucagon arm can raise heart rate and influence the liver, those have been watched specifically in studies. Because mazdutide is still investigational in the United States, longer-term risks are not fully characterized, and any effects of use outside a monitored trial are not established. On top of the compound itself, gray-market supply is its own hazard: research-grade vials can carry contamination, endotoxins, or an identity that does not match the label, and none of that is visible in the vial.

Regulatory status

Mazdutide is not FDA-approved in the United States. It was approved by China's NMPA for chronic weight management, but that is a separate regulator reviewing a separate pharmaceutical product; in the United States it remains investigational. Research-grade mazdutide sold for lab use is intended for laboratory research only, not for human use, and effects in humans are still being studied. If you have seen it lined up next to FDA-approved metabolic drugs, those are different, separately reviewed products — mazdutide is not one of them in the United States.

References & sources

1. GLORY-1: a randomised, double-blind, placebo-controlled phase 3 trial of mazdutide in Chinese adults with overweight or obesity (trial registry entry).
2. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of the GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289.